Pre-Fusion glycoprotein F0蛋白-ACROBiosystems百普赛斯

HRSV (A) Pre-fusion glycoprotein F0, His Tag (MALS verified)

表达区间及表达系统（Source）

HRSV (A) Fusion glycoprotein F0, His Tag (RSF-V52H7) is expressed from human 293 cells (HEK293).

Predicted N-terminus: Gln 26

蛋白结构（Molecular Characterization）

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 56.1 kDa. The protein migrates as 60-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素（Endotoxin）

Less than 1.0 EU per μg by the LAL method.

纯度（Purity）

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂（Formulation）

Supplied as 0.2 μm filtered solution in PBS with trehalose as protectant.

Contact us for customized product form or formulation.

运输（Shipping）

This product is supplied and shipped with dry ice, please inquire the shipping cost.

存储（Storage）

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

The product MUST be stored at -70°C or lower upon receipt;

-70°C for 3 months under sterile conditions.

背景（Background）

Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation. Both states exhibit epitopes targeted by neutralizing antibodies, and post-fusion RSV F is being developed as a vaccine candidate.